logo
Plus   Neg
Share
Email

Brink's Guides FY20 Below Estimates - Quick Facts

While reporting financial results for the fourth quarter on Thursday, The Brink's Co. (BCO) initiated its adjusted earnings and revenue guidance for the full-year 2020, below analysts' estimates.

For fiscal 2020, the company now projects adjusted earnings from continuing operations in a range of $4.30 to $4.50 per share on revenue growth of about 3 percent to $3.775 billion, with organic revenue growth of about 5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $4.64 per share on revenue growth of 5.4 percent to $3.90 billion for the year. Analysts' estimates typically exclude special items.

Separately, Brink's announced that its board of directors approved a $250 million share repurchase authorization that expires on December 31, 2021. The authorization replaces the company's previous share repurchase program, which expired December 31, 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered. Gilead Sciences Inc. said it is donating its existing supply of 1.5 million individual doses of remdesivir, its investigational medicine for coronavirus or Covid-19. The drug, which is yet to get regulatory approval, is available for compassionate use, expanded access and clinical trials to treat patients with the most severe symptoms of COVID-19.
Follow RTT
>